Treatment Algorithm for Stage IV NSCLC Patients (IMAGE)

Chinese Medical Journals Publishing House Co., Ltd.

Treatment Algorithm for Stage IV NSCLC Patients

Caption

ALK: Anaplastic lymphoma kinase; BRAF: B-raf proto-oncogene, serine/threonine kinase; CDK: Cyclin-dependent kinase; EGFR: Epidermal growth factor receptor; JAK: Janus kinase; MEK: Mitogen-activated protein kinase kinase; MET: Mesenchymal-epithelial transition factor; mTOR: Mechanistic target of rapamycin; NSCLC: Non-small cell lung cancer; PI3K: Phosphoinositide 3-kinase; RET: Rearranged during transfection; ROS1: C-ros oncogene 1; STAT: Signal transducer and activator of transcription; TKI: Tyrosine kinase inhibitor.

Credit

: Prof. Yuankai Shi from National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Image source link: https://journals.lww.com/cmj/fulltext/2026/04050/epidermal_growth_factor_receptor_tyrosine_kinase.2.aspx

Usage Restrictions

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.

License

CC BY-NC-ND

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.